Azzad Asset Management Inc /Adv Exelixis, Inc. Transaction History

Azzad Asset Management Inc /Adv

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 Apr 01, 2024	SELL	$14.46 - $21.8 $186,823 - $281,656	-12,920 Closed	0 $0
Q3 2019 Apr 01, 2024	SELL	$17.68 - $22.65 $347,871 - $445,661	-19,676 Reduced 60.36%	12,920 $268 Million
Q2 2019 Apr 01, 2024	BUY	$18.93 - $24.75 $33,638 - $43,980	1,777 Added 5.77%	32,596 $697 Million
Q1 2019 Apr 01, 2024	BUY	$19.6 - $24.76 $27,812 - $35,134	1,419 Added 4.83%	30,819 $733 Million
Q4 2018 Apr 01, 2024	BUY	$13.65 - $21.8 $401,310 - $640,920	29,400 New	29,400 $578 Million

460

240M

2.04M

1.29M

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $8.35B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

Get notified when there are updates to the investment portfolio of Azzad Asset Management Inc /Adv, based on Form 13F filings with the SEC.

Stay updated on Azzad Asset Management Inc /Adv with notifications on news.